TY - JOUR
T1 - Results of a salvage treatment program for relapsing lymphoma
T2 - MINE consolidated with ESHAP
AU - Rodriguez, M. A.
AU - Cabanillas, F. C.
AU - Velasquez, W.
AU - Hagemeister, F. B.
AU - McLaughlin, P.
AU - Swan, F.
AU - Romaguera, J. E.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1995/7
Y1 - 1995/7
N2 - Purpose: We report the results of a prospective trial in which patients with relapsing non-Hodgkin's lymphomas were sequentially treated with two regimens (mesna, ifosfamide, mitoxantrone, and etoposide [MINE], and etoposide, methylprednisolone, cytarabine, and cisplatin [ESHAP]) if they had no history of disease resistance to these drugs. Patients and Methods: Ninety-two patients received MINE (mesna 4 g/m2, ifosfamide 4 g/m2, mitoxantrone 8 mg/m2, and etoposide 195 mg/m2) for a maximum of six courses followed by ESHAP (etoposide 240 mg/m2, methylprednisone 500 mg/d, high- dose cytarabine 2 g/m2, and cisplatin 100 mg/m2) for three courses to consolidate complete response (CR) or for a maximum of six cycles after a partial response (PR) or no response to MINE. Pretreatment serum levels of lactate dehydrogenase (LDH) and β2-microglobulin (β2M) were documented in 80 of 92 patients. Results: The response rate to MINE-ESHAP was 69% (48% CRs and 21% PRs), with a median survival time of 24 months and median time to treatment failure of 12 months. The median time to treatment failure according to histology was as follows: low-grade histologies, 16 months; low- grade transformed to intermediate-grade, 8 months; and intermediate-grade, 5 months. The most serious complication was myelosuppression, which resulted in two deaths due to neutropenic sepsis. A risk factor model based on β2M and LDH levels before salvage treatment showed three categories of risk, with 36- month survival rates as follows: low (β2M < 3 mg/dL and LDH normal), 61%; intermediate (β2M ≥ 3 mg/dL or LDH above normal), 23%; and high (β2M ≥ 3 mg/dL and LDH above normal), 0%. Conclusion: MINE-ESHAP is an effective salvage strategy for patients with recurrent lymphoma. Toxicity was acceptable. Factors that determine prognostic categories at relapse merit further study.
AB - Purpose: We report the results of a prospective trial in which patients with relapsing non-Hodgkin's lymphomas were sequentially treated with two regimens (mesna, ifosfamide, mitoxantrone, and etoposide [MINE], and etoposide, methylprednisolone, cytarabine, and cisplatin [ESHAP]) if they had no history of disease resistance to these drugs. Patients and Methods: Ninety-two patients received MINE (mesna 4 g/m2, ifosfamide 4 g/m2, mitoxantrone 8 mg/m2, and etoposide 195 mg/m2) for a maximum of six courses followed by ESHAP (etoposide 240 mg/m2, methylprednisone 500 mg/d, high- dose cytarabine 2 g/m2, and cisplatin 100 mg/m2) for three courses to consolidate complete response (CR) or for a maximum of six cycles after a partial response (PR) or no response to MINE. Pretreatment serum levels of lactate dehydrogenase (LDH) and β2-microglobulin (β2M) were documented in 80 of 92 patients. Results: The response rate to MINE-ESHAP was 69% (48% CRs and 21% PRs), with a median survival time of 24 months and median time to treatment failure of 12 months. The median time to treatment failure according to histology was as follows: low-grade histologies, 16 months; low- grade transformed to intermediate-grade, 8 months; and intermediate-grade, 5 months. The most serious complication was myelosuppression, which resulted in two deaths due to neutropenic sepsis. A risk factor model based on β2M and LDH levels before salvage treatment showed three categories of risk, with 36- month survival rates as follows: low (β2M < 3 mg/dL and LDH normal), 61%; intermediate (β2M ≥ 3 mg/dL or LDH above normal), 23%; and high (β2M ≥ 3 mg/dL and LDH above normal), 0%. Conclusion: MINE-ESHAP is an effective salvage strategy for patients with recurrent lymphoma. Toxicity was acceptable. Factors that determine prognostic categories at relapse merit further study.
UR - http://www.scopus.com/inward/record.url?scp=0029044083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029044083&partnerID=8YFLogxK
U2 - 10.1200/JCO.1995.13.7.1734
DO - 10.1200/JCO.1995.13.7.1734
M3 - Article
C2 - 7602363
AN - SCOPUS:0029044083
SN - 0732-183X
VL - 13
SP - 1734
EP - 1741
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 7
ER -